Incidences and Treatments for Buruli Ulcer

Tim Sandle

School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK

Corresponding author: Sandle Tim, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK, Tel: 07808906409; E-mail: timsandle@btinternet.com

Received date: July 27, 2015; Accepted date: July 28, 2015, Published date: July 29, 2015

Copyright: © 2015 Sandle T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Buruli ulcer is a bacterial disease, alternatively called Bairnsdale ulcer, Sears ulcer, or Daintree ulcer. The tropical disease causes blood clots on the skin and, when untreated, leads to severe ulceration. The infectious disease caused by a bacterium called Mycobacterium ulcerans. It is the third most common mycobacterial disease after tuberculosis and leprosy.

The necrotizing disease occurs in parts of West Africa, Australia and Southeast Asia, affecting around 5,000 people each year [1]. Children aged under 15 are the most commonly infected demographic group and the region with the highest concentration of infections is, currently, Cote d'Ivoire. Until the late 1990s, when World Health Organization (WHO) programs began, the disease was a 'neglected disease' [2].

The current treatment option primarily involves courses of antibiotics. More serious or untreatable cases require surgical intervention. To improve current treatment regimes, scientists are investigating alternative approaches; this article assesses some of these approaches alongside current practices.

Analysis of the Disease

Infection with the M. ulcerans bacterium leads to skin nodules forming on the skin and within subcutaneous tissues. When unchecked these nodules and plaques lead to ulceration, of a characteristic white-yellow coloration. This can extend to 15% of the skin surface. If the ulcer progresses skin is lost to the extent that bone is affected. Unlike comparable diseases there is an absence of an acute inflammatory response.

The disease is manifest in different forms: indurated subcutaneous nodules, plaques, ulcers and oedema. The pain associated with the ulcer and be accompanied by fever. Many ulcers heal, however those infected can be left with scars and disabling contractures.

The common term applied to the condition - Buruli ulcer – relates to the former Buruli county (now Nakasongola) in Uganda where a number of cases of the disease were noted and studied [3]. The first cases of the disease were notified during the 1930s in the Bairnsdale District of Victoria, Australia, although accounts from the Victorian era recount probable infections [4]. Humans and animals are affected.

How someone becomes infected is unclear. Some researchers think that there is a connection between the bacteria and water sources (perhaps through water insect transmission via Naucoris or Diplonychus). Despite the association with vegetated stagnant waters, this similarity means that similar treatments can be considered, namely anticoagulant medicines. Trials, published in 2015,
have shown that anticoagulants promote healing faster than antibiotics alone [9]. Anticoagulants help to reduce the lesion size, providing a smaller target area for the antibiotic.

The research has found that M. ulcerans produces a macrolide toxin called mycolactone, which is a major virulence determinant [10]. Guinea pig studies have shown that mycolactone causes the extensive tissue damage and immunosuppression associated with a Buruli ulcer.

Mycolactone affects endothelial cells, which line blood vessels and form capillaries [11]. These cells function to prevent blood from clotting inside the vessels. Mycolactone functions to reduce the ability of endothelial cells to anticoagulate blood. This is through blocking the expression of the protein thrombomodulin. On this basis the researchers concluded that anticoagulants could improve response to antibiotics in patients.

In terms of prevention, research has been undergoing on developing a vaccine. A vaccine against M. ulcerans could be administered to protect people in at risk areas. A vaccine could also be used as to reduce treatment time and to guard against relapses of the disease [12]. There are three potential vaccine types: mycolactone-directed vaccines; attenuated live vaccines; and subunit protein vaccines. A probable vaccine candidate, and upon which most research has been centred, is live attenuated Mycobacterium bovis (also termed Bacillus Calmette-Guérin.) M. bovis causes tuberculosis in cattle [13].

Summary

Buruli ulcer is a damaging bacterial disease associated with tropical climates. The focal point for the cases and the current treatment points means that control of the disease is achievable and its elimination might one day be considered, provided that funding and resources are made available. New treatment options, such as the use of anticoagulants, can further help towards the realization of this goal.

A related area to addressing the disease and lowering incidences is with health promotion and education. Ensuring that the local population more fully understand the risks and causative factors will help lower the incident rate.

References